BIAF · ATM cap raised $5.2M

bioAffinity Technologies filed a 424B5 prospectus supplement to correct a typographical error in the prior supplement and increase the ATM offering cap by up to $5,228,226 in common stock through WallachBeth Capital. The company has already sold 114,672 shares for ~$1.3M under the existing ATM agreement. With a market cap of only $4M and a recent stock price of $2.91, this additional ATM capacity represents massive potential dilution relative to current market value, and the company has a going concern opinion with persistent net losses.

• ATM program cap increased by up to $5,228,226 in common stock through WallachBeth Capital
• 114,672 shares already sold for ~$1.3M under the existing ATM agreement since May 2025
• Last reported sale price on October 30, 2026 was $2.91 per share
• Market cap is approximately $4M as of analysis time